Researchers at Hangzhou Cancer Hospital Report New Data on Cancer (Systemic Immune-inflammation Index Predicts Prognosis and Responsiveness To Immunotherapy In Cancer Patients: a Systematic Review and Meta-analysis).

A study conducted at Hangzhou Cancer Hospital in Zhejiang, China, explored the systemic immune-inflammation index (SII) as a prognostic factor for cancer patients undergoing immunotherapy. The research found that a higher SII level was associated with lower objective response rates, worse disease control rates, shorter overall survival, and unfavorable progression-free survival. The study suggests that a high SII level could serve as a non-invasive biomarker for predicting poor tumor response and adverse prognosis in advanced cancer patients receiving immunotherapy. [Extracted from the article]